<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Glynn, Robert</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Rosuvastatin in the Prevention of Stroke among Men and Women with Elevated Levels of C-Reactive Protein: The JUPITER Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-12</style></pages><abstract><style  face="normal" font="default" size="100%">Evidence from the Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin [JUPITER; NCT00239681] trial [Ridker PM et al. N Engl J Med 2008] provides support for the use of statins to prevent strokes in healthy individuals with low LDL cholesterol but elevated high-sensitivity C-reactive protein levels.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>